Vaxdyn Overview
- Founded
- 2011
- Status
- Private
- Latest Deal Type
- Grant
- Latest Deal Amount
- $1.53M
- Investors
- 3
Vaxdyn General Information
Description
Developer of Immunotherapies and vaccines designed to offer prevention from infectious diseases. The company's vaccines uses antigens, immunomodulators, nanoparticles and mAbs to fight bacterial infections, enabling doctors to decrease the impact of infections caused by drug-resistant pathogens on public health.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Avda. España nº 55
- Office 16, D
- 41704 Dos Hermanas
- Spain
+34 606 00 00 00
Vaxdyn Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 07-Jul-2020 | $1.53M | 00.00 | Completed | Generating Revenue | |
| 2. Secondary Transaction - Private | 00.00 | Completed | Startup | |||
| 1. Seed Round | 01-Jan-2016 | $1.2M | $1.2M | Completed | Startup |
Vaxdyn Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Juan Infante Ph.D | Founder, Chief Executive Officer & Board Member | ||
| Manuel Montoya | Chief Operating Officer | ||
| Michael McConnell Ph.D | Chief Scientific Officer |
Vaxdyn Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Juan Infante Ph.D | Vaxdyn | Founder, Chief Executive Officer & Board Member | 000 0000 |
| Pilar Pérez-Romero Ph.D | Vaxdyn | Chairman | 000 0000 |
Vaxdyn Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CARB-X | Government | 000 0000 | 000000 0 | ||
| InSynchrony Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ministry of Economy | Government | Minority | 000 0000 | 000000 0 |